January 1, 2020Open Access

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Key Points

Key points are not available for this paper at this time.

Abstract

APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Sotirios Tsimikas

Ewa Karwatowska‐Prokopczuk

Ioanna Gouni‐Berthold

Journals

New England Journal of Medicine

Actions

Institutions

University of California, San Diego

University of Copenhagen

Oregon Health & Science University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study